Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

268.05 +14.23 (+5.60%)
Streaming Delayed Price Updated: 2:32 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Natera to Report its Second Quarter Results on August 6, 2026
From Natera, Inc.
Via Business Wire
News headline image
1 Unpopular Stock That Deserves Some Love and 2 We Question
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
3 Reasons We’re Fans of Natera (NTRA)
Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.1% to $263.44 per... 
Via StockStory
Topics Stocks
News headline image
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
From Natera, Inc.
Via Business Wire
News headline image
3 Market-Beating Stocks Worth Your Attention
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
Via StockStory
News headline image
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
From Natera, Inc.
Via Business Wire
News headline image
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves. ↗
It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months. 
Via The Motley Fool
News headline image
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Natera (NASDAQ:NTRA) and its ... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
From Natera, Inc.
Via Business Wire
News headline image
Why Natera (NTRA) Stock Is Up Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.7% in the morning session after the company announced its Signatera test rece... 
Via StockStory
Topics Artificial Intelligence
News headline image
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
From Natera, Inc.
Via Business Wire
News headline image
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
From Natera, Inc.
Via Business Wire
News headline image
1 Healthcare Stock for Long-Term Investors and 2 We Turn Down
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de... 
Via StockStory
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 We Avoid
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
Topics Retirement
News headline image
2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia) ↗
The famous hedge fund manager seems to have found a hidden gem outside of the market's most popular stock picks. 
Via The Motley Fool
News headline image
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
From Natera, Inc.
Via Business Wire
News headline image
NWI Management Dumps 42,700 MercadoLibre Shares Worth $82.4 Million ↗
MercadoLibre delivers e-commerce and fintech solutions across Latin America, leveraging an integrated digital ecosystem for regional growth. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
From Natera, Inc.
Via Business Wire
News headline image
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
From Natera, Inc.
Via Business Wire
News headline image
EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
From Natera, Inc.
Via Business Wire
News headline image
1 Mid-Cap Stock with Exciting Potential and 2 That Underwhelm
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.